Table 1. Participant characteristics at randomization (after 2-week diet, exercise, and placebo run-in period with mean weight loss of 1.3±1.4 kg).
|
Liraglutide |
||||||
|---|---|---|---|---|---|---|
| Placebo (n=98) | 1.2 mg (n=95) | 1.8 mg (n=90) | 2.4 mg (n=93) | 3.0 mg (n=93) | Orlistat (n=95) | |
| Male:female (%)a | 25:75 | 23:77 | 24:76 | 24:76 | 25:75 | 23:77 |
| Age (years)a | 45.9 (10.3) | 47.2 (9.7) | 45.5 (10.9) | 45.0 (11.1) | 45.9 (10.7) | 45.9 (9.1) |
| Weight (kg) | 97.3 (12.3) | 96.2 (13.5) | 98.0 (12.5) | 98.4 (13.0) | 97.6 (13.7) | 96.0 (11.7) |
| Body-mass index (kg m−2) | 34.9 (2.8) | 34.8 (2.6) | 35.0 (2.6) | 35.0 (2.8) | 34.8 (2.8) | 34.1 (2.6) |
| Waist (cm) | 108 (10.0) | 109 (10.4) | 108 (9.5) | 110 (10.7) | 109 (8.3) | 108 (9.7) |
| Total quality of life score | 72 (19) | 70 (17) | 74 (15) | 71 (20) | 72 (20) | 68 (20) |
a
Noted at screening. Values are mean (s.d.) unless otherwise stated. IWQoL-Lite quality of life scores ranged from 0 (worst) to 100 (best).